The combination of mitomycin C and vinblastine in the dose and schedule used in this study (6 and 5 mg/m2, respectively, every 14 days) was of little clinical efficacy in the management of metastatic breast cancer already refractory to standard chemotherapy and hormonal therapeutic approaches.
|Original language||English (US)|
|Number of pages||3|
|Journal||Cancer Treatment Reports|
|State||Published - Dec 1 1978|
ASJC Scopus subject areas
- Cancer Research